gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · KURAHealthcarePharmaceuticals

Kura Oncology, Inc. (KURA)

$7.61−22.98%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$7.61▼ 23.59% in range
Nov 4, 2025Low $7.40 · High $13.59Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Kura Oncology closed at $7.61 on Nov 4, down 22.98%, within 2.8% of its 52-week closing low. Volume of 8.2M shares was 5.02× its 20-day average (well above normal).

Split-adjusted performance: -27.7% over one month, -20.4% over six months, -22.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $20.87M, up 36.5% from a year earlier, with a net margin of -327.3%.

Short interest was 14.3M shares at the Oct 15 settlement (18.3% of float, 8.6 days to cover).

Market cap$677.0M89.0M shares
Revenue · quarter$20.9M+36.5% YoY
Diluted EPS$-0.77—
P/E · TTM—P/S 8.8×
Net margin-327.3%Gross 98.8%
Dividend yieldNone
52-week range7.40 – 13.59−44.0% from high
Volume8.2M5.02× 20-day avg
Volatility · 60d76.9%Annualised
Short % of float18.3%8.6 days to cover
Net cash$509.2MCash $519.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −29.0%1M −27.7%3M −18.0%6M −20.4%YTD −26.8%1Y −22.1%3Y −6.6%5Y −54.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum56
Revenue growth74
Net margin32
Value (low P/E)—
Size66

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short14.3M−0.7% vs prior
Days to cover8.6Settled Oct 15
% of float18.3%
Short vol. 10d62.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
KURAKura Oncology$7.61−22.98%−20.4%+36.5%−327.3%—$677.0M
OBXObsidian Therapeutics$10.99−16.93%————$678.9MCompare
DSGNDesign Therapeutics$10.63+2.80%−26.9%———$665.2MCompare
AVBPArriVent BioPharma$13.49+3.61%−54.5%———$665.2MCompare
ZVRAZevra Therapeutics$11.17+8.87%−0.7%+44.9%48.8%8.6$663.3MCompare
IMMXImmix Biopharma$7.97+3.37%−22.8%———$660.7MCompare
GERNGeron$1.08+16.13%−31.6%+17.2%−29.0%—$693.9MCompare
OLMAOlema Pharmaceuticals$7.54+2.58%−50.4%———$659.7MCompare
LXRXLexicon Pharmaceuticals$1.48+1.37%−7.5%−97.6%−4591.8%—$658.5MCompare

News about Kura Oncology

All news →
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research · Oct 27, 2026▼ NegativeKURA Stock Gains 37.6% in a Month: Here's What You Need to KnowZacks Investment Research · Sep 1, 2026▲ PositiveKura Oncology to Report Second Quarter Financial ResultsGlobeNewswire Inc. · Aug 5, 2026▲ PositiveKyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AMLGlobeNewswire Inc. · Apr 24, 2026▲ PositiveKura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibGlobeNewswire Inc. · Apr 17, 2026▲ Positive

Quick answers

What does Kura Oncology do?
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology.
What is KURA's market cap?
$676.99M, based on the Nov 4 close of $7.61.
Does Kura Oncology pay a dividend?
No regular cash dividend has been paid in the last year.
How much of KURA is sold short?
14.3M shares, 18.3% of float, as of Oct 15, 2026.
What sector is KURA in?
Healthcare, in the Pharmaceuticals industry.

About Kura Oncology

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

HQ: San Diego, CA260 employeesListed Aug 25, 2015kuraoncology.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology